🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Tecentriq 1 200 mg concentrate for solution for infusion, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  4. Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)

    Eastern Hepatobiliary Surgery Hospital

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  5. Telisotuzumab Adizutecan

    AbbVie

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  7. Thalidomide

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  8. The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  9. Tiaoshen Anti-cancer Granules

    The First People's Hospital of Lianyungang

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  10. Tinidazole oral microneedle patch

    The First People's Hospital of Lianyungang

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  11. Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  12. Tislelizumab

    BeiGene

    Recurrent or Metastatic Nasopharyngeal Cancer

    phase 3 small molecule completed

    1 trial

  13. Tislelizumab

    BeiGene

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  14. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  15. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  16. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  17. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. Trabectedin

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  19. Trastuzumab

    Mylan IRE Healthcare Limited

    Breast Cancer

    phase 3 mab completed

    1 trial

  20. Trastuzumab

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  21. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  22. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  23. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  24. Trastuzumab Deruxtecan

    AstraZeneca

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources